Brandenburg-based life science company Adrenomed announces release of the design of the Phase II Sepsis Study

Potsdam/Hennigsdorf - February 2019. Adrenomed AG, a company focused on restoring the functioning of blood vessel walls, announced on February 7, 2019 the publication of the design of the Phase II Sepsis Study with the novel active ingredient Adrecizumab in the BMJ Open journal, which has been peer-reviewed by experts. Adrecizumab is a monoclonal antibody and forms the basis for a novel approach to treating life-threatening diseases by maintaining the integrity of blood vessels.

The double-blinded, placebo-controlled and multicenter Phase II study evaluates the safety, tolerability and efficacy of the active substance Adrecizumab® in 300 patients in an early septic shock state and with an increased adrenomedullin (bio-ADM®) plasma concentration using the biomarker bio-ADM. The study started in December 2017 and is currently running in more than 30 international clinics and hospitals. To date, 150 patients have been included in the study. All information on the study was published in the BMJ Open journal.

About Adrenomed AG

Adrenomed AG is a privately-financed, biopharmaceutical company from Germany with clinical development projects. Adrenomed is pursuing a new therapeutic approach to ensuring the integrity and barrier function of blood vessels. These can become more permeable in severe diseases that are not yet treatable, such as sepsis and acute heart failure, leading to life-threatening edema and shock. The company was founded in 2009 and is led by a management team with decades of experience in the indication of sepsis and profound knowledge in diagnostics and drug development. The company's main product candidate is the monoclonal antibody Adrecizumab, which is already in clinical development. Adrecizumab, the first representative of a new class of therapy, targets the vasoprotective peptide adrenomedullin, a major regulator of vascular integrity. It is currently being clinically evaluated in a biomarker-controlled, double-blind, placebo-controlled, randomized, multicenter proof-of-concept Phase II study of 300 patients in the indication of septic shock. Excellent safety and tolerability have been demonstrated in two Phase I studies.

For more information, see www.brandenburg-kapital.de and www.adrenomed.com